Recombinant Human B7-1 Fc/CD80

Recombinant Human B7-1 Fc/CD80
Catalog Number:
310-32
Synonyms:
B7, BB1, CD80
Description:

B7-1 and B7-2 are transmembrane glycoproteins of the immunoglobulin superfamily that are expressed, along with the receptors CD28 and CTLA4, by antigen-presenting cells, and along with these receptors, constitute crucial costimulatory pathways for T and B cell regulatory responses. As members of the B7 family, B7-1 and B7-2 play principal roles in immunity, activating immune response and maintaining immune tolerance through engagement with CD28 and CTLA4. Costimulatory signals generated by B7-1 and B7-2 interactions with CD28 serve to stimulate T cell activation and prevent anergy through the amplification of T cell receptor (TCR) signaling. In contrast, interactions of the ligands with CTLA-4 serves to maintain T cell homeostasis and self-tolerance through the disruption of stimulatory signaling from B7 isoform bound CD28 complexes, and by inducing powerful inhibitory signals in T cells. B7-1 plays an important role in immune response through its amplification and regulation of T cell activity at peripheral inflammation sites. B7-1, like CTLA-4, is, however, only poorly expressed on resting dendritic cells, and its up-regulation is, therefore, considerably delayed upon immune activation. Conversely, B7-2 and CD28 are constitutively expressed by resting hematopoietic and T cells, respectively, and as a result are able to rapidly induce up-regulation upon immune activation, making them critical to the early costimulatory singling of immune response. Both B7-1 and B7-2 have been shown to demonstrate costimulatory activity in T-cell proliferation in vitro and elicit enhanced antitumor immune response in vivo. Recombinant Human B7-1Fc is a homodimeric B7-1 fusion protein, whose monomer contains a total of 441 amino acid residues, consisting of 211 amino acid residues corresponding to the extracellular domain of human B7-1, fused to the Fc portion of human IgG1. The calculated molecular weight of the B7-1 Fc monomer is 50.0 kDa.
AA Sequence:
VIHVTKEVKE VATLSCGHNV SVEELAQTRI YWQKEKKMVL TMMSGDMNIW PEYKNRTIFD ITNNLSIVIL ALRPSDEGTY ECVVLKYEKD AFKREHLAEV TLSVKADFPT PSISDFEIPT SNIRRIICST SGGFPEPHLS WLENGEELNA INTTVSQDPE TELYAVSSKL DFNMTTNHSF MCLIKYGHLR VNQTFNWNTT KQEHFPDNGG PKSCDKTHTC PPCPAPELLG GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRD ELTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG K
Source:
CHO cells
Purity:
Greater than 95% by SDS-PAGE gel and HPLC analyses.
Biological Activity:
Determined by its ability to inhibit alkalinephosphatase activity in differentiating MC3T3/E1 cells. The expected ED50 for this effect is 0.5-1.5 μg/ml.


Recombinant Human B7-2 Fc/CD86
Catalog Number:
310-33
Synonyms:
B70, CD86, ETC1
Description:
B7-1 and B7-2 are transmembrane glycoproteins of the immunoglobulin superfamily that are expressed, along with the receptors CD28 and CTLA4, by antigen-presenting cells, and along with these receptors, constitute crucial co-stimulatory pathways for T and B cell regulatory responses. As members of the B7 family, B7-1 and B7-2 play principal roles in immunity, activating immune response and maintaining immune tolerance through engagement with CD28 and CTLA4. Co-stimulatory signals generated by B7-1 and B7-2 interactions with CD28 serve to stimulate T cell activation and prevent anergy through the amplification of T cell receptor (TCR) signaling. In contrast, interactions of the ligands with CTLA-4 serves to maintain T cell homeostasis and self-tolerance through the disruption of stimulatory signaling from B7 isoform bound CD28 complexes, and by inducing powerful inhibitory signals in T cells. B7-1 plays an important role in immune response through its amplification and regulation of T cell activity at peripheral inflammation sites. B7-1, like CTLA-4, is, however, only poorly expressed on resting dendritic cells, and its up-regulation is, therefore, considerably delayed upon immune activation. Conversely, B7-2 and CD28 are constitutively expressed by resting hematopoietic and T cells, respectively, and as a result are able to rapidly induce up-regulation upon immune activation, making them critical to the early co-stimulatory signaling of immune response. Both B7-1 and B7-2 have been shown to demonstrate co-stimulatory activity in T-cell proliferation in vitro and elicit enhanced antitumor immune response in vivo. Recombinant Human B7-2Fc is a homodimeric B7-2 fusion protein, whose monomer contains a total of 453 amino acid residues, consisting of 222 amino acid residues corresponding to the extracellular domain of human B7-2, fused to the Fc portion of human IgG1. The calculated molecular weight of the B7-2 Fc monomer is 51.2 kDa.
AA Sequence:
LKIQAYFNET ADLPCQFANS QNQSLSELVV FWQDQENLVL NEVYLGKEKF DSVHSKYMGR TSFDSDSWTL RLHNLQIKDK GLYQCIIHHK KPTGMIRIHQ MNSELSVLAN FSQPEIVPIS NITENVYINL TCSSIHGYPE PKKMSVLLRT KNSTIEYDGV MQKSQDNVTE LYDVSISLSV SFPDVTSNMT IFCILETDKT RLLSSPFSIE LEDPQPPPDH GGPKSCDKTH TCPPCPAPEL LGGPSVFLFP PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR EPQVYTLPPS RDELTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS PGK
Source:
CHO cells
Purity:
Greater than 95% by SDS-PAGE gel and HPLC analyses.
Biological Activity:
Determined by its ability to inhibit alkaline phosphatase activity in differentiating MC3T3/E1 cells. The expected ED50 for this effect is 0.5-1.5 μg/ml.